Abstracts tagged "nonsteroidal antiinflammatory drugs (NSAIDs) and pediatric rheumatology"

Abstract Number: 1141 • ACR/ARHP Annual Meeting 2012
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Rachel E. Sobel¹, D. J. Lovell², Hermine Brunner³, Jennifer E. Weiss⁴, Paula W. Morris⁵, Beth S. Gottlieb⁶, Elizabeth C. Chalom⁷, Lawrence K. Jung⁸, Karen Onel⁹, Lisa Petinoit¹⁰, Donald P. Goldsmith¹¹, Staci Abramsky-Risman¹², James P., Young¹³ and Edward H. Giannini¹⁴, ¹Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Hackensack Univ Med Ctr, Hackensack, NJ, ⁵Pediatrics, Univ of Arkansas for Med Sci, Little Rock, AR, ⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁷Pediatrics, St. Barnabas Medical Center, Livingston, NJ, ⁸Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Pediatric Rheumatology, 'Specially for Children, Dell Children's Medical Center, Austin, TX, ¹¹Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³United BioSource Corporation, Ann Arbor, MI, ¹⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…